Enliven Current Deferred Revenue vs Common Stock Analysis

ELVN Stock

25.41 1.06 4.35%

Enliven Therapeutics financial indicator trend analysis is much more than just examining Enliven Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Enliven Therapeutics is a good investment. Please check the relationship between Enliven Therapeutics Current Deferred Revenue and its Common Stock accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

Current Deferred Revenue vs Common Stock

Current Deferred Revenue vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Enliven Therapeutics Current Deferred Revenue account and Common Stock. At this time, the significance of the direction appears to have strong relationship.

The correlation between Enliven Therapeutics' Current Deferred Revenue and Common Stock is 0.6. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Common Stock in the same time period over historical financial statements of Enliven Therapeutics, assuming nothing else is changed. The correlation between historical values of Enliven Therapeutics' Current Deferred Revenue and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Enliven Therapeutics are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Current Deferred Revenue i.e., Enliven Therapeutics' Current Deferred Revenue and Common Stock go up and down completely randomly.

Correlation Coefficient

0.6

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Common Stock

Most indicators from Enliven Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Enliven Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.At this time, Enliven Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 28th of November 2024, Enterprise Value is likely to grow to about 411.8 M, while Issuance Of Capital Stock is likely to drop about 505.3 K.

	2021	2022	2023	2024 (projected)
Net Interest Income	22K	1.1M	12.0M	12.6M
Cost Of Revenue	99K	622K	297K	252.6K

Net Interest Income Cost Of Revenue

Enliven Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Short Term Investments	Other Liab	Net Tangible Assets	Current Deferred Revenue	Capital Lease Obligations	Net Invested Capital
Total Assets		-0.51	0.93	0.94	0.85	-0.82	-0.91	0.11	0.75	1.0	0.92	0.2	0.91	0.9	0.35	1.0	0.86	0.63	0.45	0.36	0.92	-0.86	-0.75	0.75	0.77	0.86
Short Long Term Debt Total	-0.51		-0.33	-0.39	-0.14	0.63	0.44	-0.53	-0.62	-0.51	-0.27	-0.57	-0.28	-0.24	-0.56	-0.5	-0.2	-0.37	-0.03	0.09	-0.29	0.25	0.45	-0.35	-0.33	-0.2
Other Current Liab	0.93	-0.33		0.99	0.94	-0.56	-0.97	0.0	0.48	0.92	0.99	-0.1	1.0	0.98	0.05	0.93	0.97	0.61	0.64	0.6	0.95	-0.94	-0.69	0.75	0.8	0.95
Total Current Liabilities	0.94	-0.39	0.99		0.9	-0.6	-0.99	0.1	0.53	0.93	0.97	-0.01	0.98	0.96	0.14	0.94	0.94	0.68	0.68	0.62	0.92	-0.91	-0.76	0.81	0.85	0.91
Total Stockholder Equity	0.85	-0.14	0.94	0.9		-0.43	-0.84	-0.34	0.34	0.84	0.97	-0.32	0.96	0.98	-0.18	0.85	0.99	0.33	0.45	0.46	0.98	-0.93	-0.46	0.54	0.59	1.0
Net Debt	-0.82	0.63	-0.56	-0.6	-0.43		0.58	-0.4	-0.99	-0.83	-0.53	-0.7	-0.5	-0.49	-0.79	-0.82	-0.42	-0.62	-0.17	0.0	-0.55	0.46	0.73	-0.64	-0.61	-0.43
Retained Earnings	-0.91	0.44	-0.97	-0.99	-0.84	0.58		-0.2	-0.51	-0.9	-0.94	-0.02	-0.95	-0.92	-0.17	-0.9	-0.9	-0.73	-0.74	-0.68	-0.86	0.86	0.78	-0.85	-0.89	-0.86
Accounts Payable	0.11	-0.53	0.0	0.1	-0.34	-0.4	-0.2		0.43	0.11	-0.11	0.76	-0.09	-0.18	0.76	0.1	-0.24	0.71	0.36	0.2	-0.23	0.17	-0.63	0.51	0.45	-0.31
Cash	0.75	-0.62	0.48	0.53	0.34	-0.99	-0.51	0.43		0.77	0.45	0.75	0.42	0.41	0.83	0.75	0.33	0.61	0.15	-0.01	0.47	-0.35	-0.69	0.63	0.59	0.34
Cash And Short Term Investments	1.0	-0.51	0.92	0.93	0.84	-0.83	-0.9	0.11	0.77		0.91	0.22	0.9	0.89	0.36	1.0	0.85	0.62	0.43	0.33	0.91	-0.85	-0.74	0.74	0.76	0.85
Common Stock Shares Outstanding	0.92	-0.27	0.99	0.97	0.97	-0.53	-0.94	-0.11	0.45	0.91		-0.16	0.99	1.0	-0.01	0.92	0.99	0.53	0.59	0.55	0.98	-0.95	-0.65	0.7	0.74	0.97
Non Current Liabilities Total	0.2	-0.57	-0.1	-0.01	-0.32	-0.7	-0.02	0.76	0.75	0.22	-0.16		-0.18	-0.22	0.98	0.2	-0.3	0.51	-0.06	-0.24	-0.18	0.2	-0.49	0.34	0.28	-0.32
Other Current Assets	0.91	-0.28	1.0	0.98	0.96	-0.5	-0.95	-0.09	0.42	0.9	0.99	-0.18		0.99	-0.03	0.91	0.99	0.54	0.62	0.59	0.96	-0.94	-0.63	0.7	0.76	0.97
Other Stockholder Equity	0.9	-0.24	0.98	0.96	0.98	-0.49	-0.92	-0.18	0.41	0.89	1.0	-0.22	0.99		-0.07	0.9	1.0	0.47	0.56	0.54	0.98	-0.95	-0.58	0.65	0.71	0.99
Total Liab	0.35	-0.56	0.05	0.14	-0.18	-0.79	-0.17	0.76	0.83	0.36	-0.01	0.98	-0.03	-0.07		0.35	-0.16	0.61	0.05	-0.15	-0.04	0.06	-0.61	0.46	0.41	-0.18
Total Current Assets	1.0	-0.5	0.93	0.94	0.85	-0.82	-0.9	0.1	0.75	1.0	0.92	0.2	0.91	0.9	0.35		0.86	0.62	0.44	0.35	0.92	-0.86	-0.74	0.74	0.76	0.86
Common Stock	0.86	-0.2	0.97	0.94	0.99	-0.42	-0.9	-0.24	0.33	0.85	0.99	-0.3	0.99	1.0	-0.16	0.86		0.41	0.54	0.54	0.97	-0.95	-0.52	0.6	0.66	0.99
Property Plant And Equipment Net	0.63	-0.37	0.61	0.68	0.33	-0.62	-0.73	0.71	0.61	0.62	0.53	0.51	0.54	0.47	0.61	0.62	0.41		0.8	0.65	0.38	-0.43	-0.94	0.93	0.93	0.33
Non Current Assets Total	0.45	-0.03	0.64	0.68	0.45	-0.17	-0.74	0.36	0.15	0.43	0.59	-0.06	0.62	0.56	0.05	0.44	0.54	0.8		0.98	0.41	-0.43	-0.68	0.86	0.87	0.46
Non Currrent Assets Other	0.36	0.09	0.6	0.62	0.46	0.0	-0.68	0.2	-0.01	0.33	0.55	-0.24	0.59	0.54	-0.15	0.35	0.54	0.65	0.98		0.39	-0.39	-0.52	0.76	0.77	0.46
Short Term Investments	0.92	-0.29	0.95	0.92	0.98	-0.55	-0.86	-0.23	0.47	0.91	0.98	-0.18	0.96	0.98	-0.04	0.92	0.97	0.38	0.41	0.39		-0.93	-0.54	0.57	0.61	0.99
Other Liab	-0.86	0.25	-0.94	-0.91	-0.93	0.46	0.86	0.17	-0.35	-0.85	-0.95	0.2	-0.94	-0.95	0.06	-0.86	-0.95	-0.43	-0.43	-0.39	-0.93		0.56	-0.52	-0.61	-0.94
Net Tangible Assets	-0.75	0.45	-0.69	-0.76	-0.46	0.73	0.78	-0.63	-0.69	-0.74	-0.65	-0.49	-0.63	-0.58	-0.61	-0.74	-0.52	-0.94	-0.68	-0.52	-0.54	0.56		-0.89	-0.87	-0.46
Current Deferred Revenue	0.75	-0.35	0.75	0.81	0.54	-0.64	-0.85	0.51	0.63	0.74	0.7	0.34	0.7	0.65	0.46	0.74	0.6	0.93	0.86	0.76	0.57	-0.52	-0.89		0.98	0.54
Capital Lease Obligations	0.77	-0.33	0.8	0.85	0.59	-0.61	-0.89	0.45	0.59	0.76	0.74	0.28	0.76	0.71	0.41	0.76	0.66	0.93	0.87	0.77	0.61	-0.61	-0.87	0.98		0.6
Net Invested Capital	0.86	-0.2	0.95	0.91	1.0	-0.43	-0.86	-0.31	0.34	0.85	0.97	-0.32	0.97	0.99	-0.18	0.86	0.99	0.33	0.46	0.46	0.99	-0.94	-0.46	0.54	0.6

Click cells to compare fundamentals

Enliven Therapeutics Account Relationship Matchups

Enliven Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	33.3M	131.0M	113.3M	83.3M	271.9M	285.5M
Other Current Liab	2.5M	565K	3.1M	6.0M	25.0M	26.3M
Total Current Liabilities	4.2M	1.5M	5.8M	9.7M	25.9M	27.2M
Total Stockholder Equity	(48.8M)	(20.3M)	(42.9M)	(76.8M)	245.9M	258.2M
Net Debt	(4.9M)	(130.3M)	(109.9M)	(75.2M)	(99.8M)	(94.8M)
Retained Earnings	(54.8M)	(20.5M)	(45.2M)	(82.9M)	(154.4M)	(146.7M)
Accounts Payable	1.7M	808K	2.5M	3.4M	532K	505.4K
Cash	4.9M	130.4M	110.0M	75.5M	100.1M	68.8M
Cash And Short Term Investments	28.9M	130.4M	110.0M	75.5M	253.1M	265.8M
Liabilities And Stockholders Equity	33.3M	131.0M	113.3M	83.3M	271.9M	285.5M
Non Current Liabilities Total	184.0K	149.8M	150.5M	150.4M	67K	63.7K
Other Current Assets	1.7M	222K	646K	2.2M	13.0M	13.7M
Other Stockholder Equity	5.9M	157K	2.3M	6.2M	400.2M	420.2M
Total Liab	4.4M	151.3M	156.2M	160.1M	26.0M	24.7M
Total Current Assets	30.6M	130.6M	110.7M	77.8M	266.2M	279.5M

Pair Trading with Enliven Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Enliven Stock

0.83	FDMT	4D Molecular Therapeutics	Pair Corr
0.71	RGNX	Regenxbio	Pair Corr
0.67	INKT	Mink Therapeutics	Pair Corr
0.62	NKTX	Nkarta Inc Buyout Trend	Pair Corr
0.6	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.

The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:

How To Invest In Enliven

Details

Is Enliven Stock a good investment?

Details

What is Enliven Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.89)

Return On Assets

(0.21)

Return On Equity

(0.31)

The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enliven Current Deferred Revenue vs Common Stock Analysis

Current Deferred Revenue vs Common Stock

Current Deferred Revenue vs Common Stock Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Common Stock

Enliven Therapeutics fundamental ratios Correlations

Enliven Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enliven Therapeutics fundamental ratios Accounts

Pair Trading with Enliven Therapeutics

Moving against Enliven Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Other Current Liab
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Stockholder Equity	+ 1.0	Common Stock Shares Outstanding

Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Total Current Liabilities
Retained Earnings	- 0.97	Other Current Liab
Other Liab	- 0.95	Common Stock
Other Liab	- 0.95	Other Stockholder Equity
Other Liab	- 0.95	Common Stock Shares Outstanding